Microgynon 50 (Ethinylestradiol, Levonorgestrel)

Microgynon 50 is a combined hormonal contraceptive that acts on the reproductive endocrine system.

• Contraception: provides reliable prevention of pregnancy for women of child‑bearing potential.
• Regulation of menstrual cycles: helps achieve more predictable and lighter bleeding patterns.
• Acne treatment: reduces inflammatory acne lesions by modulating androgen activity.

• Ethinylestradiol and levonorgestrel work together to suppress the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinising hormone and thereby inhibiting ovulation. The estrogen component stabilises the endometrial lining, while the progestogen thickens cervical mucus and alters the endometrium, creating an environment unsuitable for fertilisation and implantation.

Microgynon 50 may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort of the breasts.
• Spotting or breakthrough bleeding: irregular light bleeding between periods.
• Mood changes: irritability or mild depressive symptoms.
• Weight gain: modest increase in body weight, usually fluid‑related.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in the legs.
• Pulmonary embolism: clot migration to the lungs, a medical emergency.
• Stroke or myocardial infarction: rare cerebrovascular or cardiac events.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Liver tumor: benign hepatic adenoma, especially with prolonged use.
• Hypertension: new‑onset or worsening high blood pressure.

Before prescribing Microgynon 50, clinicians should evaluate individual risk factors and counsel patients on safe use.

• Medical review: assess history of thromboembolic disorders, cardiovascular disease, or liver dysfunction.
• Smoking: avoid use in women over 35 who smoke, due to increased clot risk.
• Medication review: consider potential interactions with enzyme‑inducing drugs.
• Pregnancy: discontinue immediately if pregnancy is confirmed; the product is not indicated for use during pregnancy.
• Breastfeeding: discuss benefits and risks with a healthcare professional before use.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Microgynon 50 can interact with several drug classes, affecting contraceptive efficacy or hormone levels.

Major Interactions (Avoid)

• Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): markedly reduce hormonal effectiveness.
• Rifampicin: lowers plasma concentrations of both estrogen and progestogen.
• Protease inhibitor ritonavir: may increase hormone levels, raising risk of side effects.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., ketoconazole, itraconazole): can elevate hormone concentrations.
• St. John’s wort: may modestly decrease contraceptive efficacy.
• Certain antibiotics (e.g., tetracycline, metronidazole): may slightly reduce protection, warranting backup contraception.